scholarly journals Cost Analysis of Health Examination Screening Program for Ischemic Heart Disease in Active-Duty Military Personnel in the Middle-Income Country

2021 ◽  
Vol 9 ◽  
Author(s):  
Radoje Simic ◽  
Nenad Ratkovic ◽  
Viktorija Dragojevic Simic ◽  
Zorica Savkovic ◽  
Mihajlo Jakovljevic ◽  
...  
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Arterial Hypertension ◽  
Military Personnel ◽  
Screening Program ◽  
Active Duty ◽  
Ischemic Heart ◽  
Health Examination ◽  
Periodic Health Examination ◽  
Active Duty Military

Cardiovascular diseases, including ischemic heart disease, are the most common causes of morbidity and death in the world, including Serbia, as a middle-income European country. The aim of the study was to determine the costs of preventive examinations for ischemic heart disease in active-duty military personnel, as well as to assess whether this was justified from the point of view of the limited health resources allocated for the treatment of the Republic of Serbia population. This is a retrospective cost-preventive study which included 738 male active-duty military personnel, aged from 23 to 58. The costs of primary prevention of ischemic heart disease in this population were investigated. Out of 738 subjects examined, arterial hypertension was detected in 101 subjects (in 74 of them, arterial hypertension was registered for the first time, while 27 subjects were already subjected to pharmacotherapy for arterial hypertension). Average costs of all services during the periodic-health-examination screening program were €76.96 per subject. However, average costs of all services during the periodic-health-examination screening program for patients with newfound arterial hypertension and poorly regulated arterial hypertension were €767.54 per patient and €2,103.63 per patient, respectively. Since periodic-health-examination screening program in military personnel enabled not only discovery of patient with newfound arterial hypertension but also regular monitoring of those who are already on antihypertensive therapy, significant savings of €690.58 per patient and €2,026.67 per patient can be achieved, respectively. As financial resources for providing health care in Serbia, as a middle-income country, are limited, further efforts should be put on screening programs for ischemic heart disease due to possible significant savings.

scholarly journals Gender Differences in the Risk of Ischemic Heart Disease According to Healthcare Utilization and Medication Adherence among Newly Treated Korean Hypertensive Patients

2021 ◽  
Vol 18 (3) ◽  
pp. 1274
Author(s):  
Jiae Shin ◽  
Dongwoo Ham ◽  
Hee Young Paik ◽  
Sangah Shin ◽  
Hyojee Joung
Keyword(s):  
Gender Differences ◽  
Heart Disease ◽  
Medication Adherence ◽  
Ischemic Heart Disease ◽  
Healthcare Utilization ◽  
Healthcare Providers ◽  
Ischemic Heart ◽  
Health Examination ◽  
Men And Women ◽  
Hypertensive Patients

We aimed to investigate gender differences in ischemic heart disease (IHD) according to healthcare utilization and medication adherence among newly treated Korean hypertensive adults. The National Sample Cohort version 2.0 of the National Health Insurance Service was used for analysis. Newly treated hypertensive patients ≥ 20 years and without IHD in 2002 were selected from a population that underwent health examination during 2003–2006. Of those patients, 11,942 men and 11,193 women were analyzed and followed up for 10 years. We determined the association between IHD and healthcare utilization and medication adherence using the Cox proportional hazards model. Hypertensive women patients had a lower risk of IHD than men patients (hazard ratio [HR] = 0.93, 95% confidence interval [CI] 0.88–1.00). The IHD risk was increased in patients who visited healthcare providers > 12 times/person-year (HR = 2.97, 95% CI 2.79–3.17), paid high out-of-pocket expense/person-year (HR = 1.55, 95% CI 1.41–1.69), and had medication nonadherence (HR = 1.67, 95% CI 1.58–1.77). However, the risk was decreased in patients who used both urban and rural areas (HR 0.75, 95% CI 0.67–0.84) and mixed types of providers (HR = 0.93, CI 0.88–0.99). The risk of IHD was significantly different between men and women only in the visiting frequency to healthcare providers (men, HR = 3.21, 95% CI 2.93–3.52; women, HR = 2.78, 95% CI 2.53–3.04, p for interaction = 0.0188). In summary, the risk of IHD was similar according to healthcare utilization and medication adherence between men and women, except visiting frequency to healthcare providers.

scholarly journals Felodipine in Treatment of Arterial Hypertension and Ischemic Heart Disease

2020 ◽  
Vol 16 (4) ◽  
pp. 654-662
Author(s):  
O. D. Ostroumova ◽  
I. A. Alautdinova ◽  
A. I. Kochetkov ◽  
S. N. Litvinova
Keyword(s):  
Chronic Kidney Disease ◽  
Heart Disease ◽  
Kidney Disease ◽  
Ischemic Heart Disease ◽  
Arterial Hypertension ◽  
Ischemic Heart ◽  
Sufficient Evidence ◽  
Clinical Effects ◽  
First Line ◽  
Wide Range

Cardiovascular diseases are the leading cause of death both in the world and in the Russian Federation. The most significant contributors to the increase in mortality are arterial hypertension (AH) and ischemic heart disease (IHD). Dihydropyridine calcium channel blockers (CCBs) are the first line of treatment for these conditions. This is noted in the clinical guidelines for the diagnosis and treatment of AH and in the guidelines for the management of patients with chronic coronary syndromes. CCBs are a heterogeneous group of drugs that have both general and individual pharmacokinetic and pharmacodynamic properties. They are used in patients with AH and/or IHD, including those with concomitant diseases (diabetes mellitus, chronic kidney disease, bronchial asthma, chronic obstructive pulmonary disease, peripheral arterial disease). Felodipine is one of the CCBs. It has a combination of clinical effects, allowing the drug to be prescribed as a first-line therapy for AH, IHD and a combination of these diseases. This is noted in the registered indications for its use. This CCB has a sufficient evidence base of clinical trials demonstrating not only good antihypertensive and antianginal potential of the drug, but also the nephroprotection and cerebroprotection properties. The nephroprotective effect of felodipine is associated with a slowdown in the progression of chronic kidney disease, and the cerebroprotective effect is associated with a decrease in the risk of stroke and an improvement in cognitive functioning. The safety profile of felodipine is favorable: peripheral edema develops much less frequently. This is confirmed by the results of comparative studies. Felodipine is recommended for a wide range of patients with AH, IHD and their combination due to such clinical and pharmacological properties.

scholarly journals Efficiency of Esmolol in Treating Postoperative Arterial Hypertension in Patients with Ischemic Heart Disease

2021 ◽  
Vol 9 (4) ◽  
Author(s):  
Abbasov Fazil ◽  
Mahmudov Reshad, ◽  
Musayev Seymur ◽  
Kurbanov Emil ◽  
Isayeva Aynur
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Arterial Hypertension ◽  
Ischemic Heart

scholarly journals Effect of Perindopril / Amlodipine Fixed Combination on Ultrasound Characteristics of Ventricles of the Heart in Patients with Ischemic Heart Disease and Arterial Hypertension

Kardiologiia ◽  
2019 ◽  
Vol 59 (1) ◽  
pp. 22-27 ◽  
Author(s):  
N. V. Drobotya ◽  
S. S. Torosyan ◽  
E. Sh. Guseynova ◽  
M. N. Morgunov
Keyword(s):  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Arterial Hypertension ◽  
Fixed Combination ◽  
Ischemic Heart ◽  
Fixed Dose ◽  
Significant Positive Effect ◽  
Dose Combination ◽  
Left And Right ◽  
Positive Effect

In a group of 32 patients with combined ischemic heart disease (IHD) and arterial hypertension (AH) we studied dynamics of parameters of blood pressure and ECG 24-hour monitoring, as well as ultrasound structural and functional parameters of left and right ventricles during 3-month therapy with fixed dose combination of perindopril arginine (10.0 mg) and amlodipine (5.0 mg). The obtained results demonstrated significant positive effect of this combination on the geometry, structure and diastolic function of both left and right ventricles, as well as confirmed its high antiischemic and antihypertensive effects.

Sign in / Sign up

Export Citation Format

Share Document